Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at San Francisco, California
Dates
study started
estimated completion
Principal Investigator
by Clark Rosen, MD
Headshot of Clark Rosen
Clark Rosen

Description

Summary

Spasmodic Dysphonia (SD) is a neurologic condition causing inappropriate contraction of the laryngeal musculature, leading to abnormal voicing. The three types (adductor, abductor, and mixed) affect varying muscle groups which produce characteristic voice patterns. The vast majority of patients with SD have adductor type, which impacts the lateral cricoarytenoid and thyroarytenoid muscle complex. While many treatment modalities have been investigated, the most effective treatment is botulinum toxin injection to these muscle groups, performed transcervically with or without electromyography (EMG) guidance. Patients undergoing this treatment typically require re-injection every 3 months. Due to its specialized nature, the laryngeal injections are not performed routinely outside of academic medical centers; thus, patients may come from a distance to receive this treatment. Both due to the significant impact on voice quality when the injections wear off and the sometimes challenging access to treatment, a longer-acting agent is desired. Injectible daxibotuliumtoxinA (DAXI, Revance Therapeutics Inc., Newark, CA) has been shown in large clinical trials to provide safe, effective treatment for glabellar lines and cervical dystonia and may offer a longer-lasting result when compared with onabotulinumtoxinA. Thus, a study examining the effect of DAXI for patients with adductor spasmodic dysphonia is proposed. This study aims to assess the efficacy of DAXI for transcervical laryngeal injection in patients with adductor spasmodic dysphonia.

Keywords

Adductor Spasmodic Dysphonia Voice Disorders Spasmodic Dysphonia Dysphonia Hoarseness Botulinum Toxins, Type A abobotulinumtoxinA DaxibotulinumtoxinA Administration of Daxi

Eligibility

You can join if…

Open to people ages 18 years and up

  • greater than 18
  • diagnosis of adductor spasmodic dysphonia
  • previous successful treatment with BotoxA
  • stabilized dose for last 3 treatments

You CAN'T join if...

  • age less than 18
  • exclusively having other neurologic conditions such as:
  • abductor spasmodic dysphonia
  • ALS
  • Multiple sclerosis
  • Parkinson's disease
  • Essential tremor

Location

  • UCSF
    San Francisco California 94118 United States

Lead Scientist at UCSF

  • Clark Rosen, MD
    Professor, Otolaryngology. Authored (or co-authored) 173 research publications.

Details

Status
not yet accepting patients
Start Date
Completion Date
(estimated)
Sponsor
University of California, San Francisco
ID
NCT05158166
Phase
Phase 1/2
Study Type
Interventional
Last Updated